APA (7th ed.) Citation

Tripp, C. S., Cuff, C., Campbell, A. L., Hendrickson, B. A., Voss, J., Melim, T., . . . Kim, K. (2017). RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Advances in therapy, 34(6), 1364-1381. https://doi.org/10.1007/s12325-017-0525-8

Chicago Style (17th ed.) Citation

Tripp, Catherine S., Carolyn Cuff, Andrew L. Campbell, Barbara A. Hendrickson, Jeff Voss, Terry Melim, Chengbin Wu, Andrew D. Cherniack, and Kenneth Kim. "RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study." Advances in Therapy 34, no. 6 (2017): 1364-1381. https://doi.org/10.1007/s12325-017-0525-8.

MLA (9th ed.) Citation

Tripp, Catherine S., et al. "RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study." Advances in Therapy, vol. 34, no. 6, 2017, pp. 1364-1381, https://doi.org/10.1007/s12325-017-0525-8.